NAMPT inhibitors, including FK866 and CHS828, have potent anticancer activity in several preclinical models of solid and hematologic cancers [6] by depleting NAD+ and ATP levels and thereby leading to tumor growth inhibition [6–8, 12–15]. This evidence concerns the gene NAMPT and neoplasm.